Adherence to highly active antiretroviral therapy (HAART): A meta-analysis

AIDS and Behavior

Volumn 15, Issue 7, 2011, Pages 1381-1396

  Ortego, Carmen ^a   Huedo Medina, Tania B ^b   Llorca, Javier ^a,c,d   Sevilla, Lourdes ^a   Santos, Pilar ^a   Rodríguez, Elías ^a   Warren, Michelle R ^b   Vejo, Javier ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d IFIMAV   (Spain)

Author keywords

Acquired immunodeficiency syndrome; Adherence; HAART; HIV; Human development; Meta analysis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; FEMALE; HEALTH CARE DELIVERY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; META ANALYSIS; MIDDLE AGED; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; STATISTICS; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84855178088     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-011-9942-x     Document Type: Article

References (130)

1. ONUSIDA. Global report. UNAIDS report on the global AIDS Epidemic (2010). 2010; Available at: Http://www.unaids.org/globalreport/Global-report-es.htm.
2. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279(6):450-4. (Pubitemid 28082255)
3. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet. 2003;362(9377):22-9. (Pubitemid 36835816)
4. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13):853-60. (Pubitemid 28135961)
5. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133(1):21-30. (Pubitemid 30432540)
6. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357-66. (Pubitemid 30182431)
7. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003;17: 1925-32. (Pubitemid 37070278)
8. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191(3):339-47. (Pubitemid 40139758)
9. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37(8):1112-8. (Pubitemid 37323668)
10. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9): 1181-3. (Pubitemid 32549871)
11. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50(5):529-36.
12. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIVinfected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 9 10(9) cells/L. Ann Intern Med. 2003;139(10):810-6.
13. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibidor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):930-41.
14. Turner BJ. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis. 2002; 185(Suppl 2):S143-51. (Pubitemid 34499451)
15. Fogarty L, Roter D, Larson S, Burke J, Gillespie J, Levy R. Patient adherence to HIV medication regimens: A review of published and abstract reports. Patient Educ Couns. 2002;46(2): 93-108. (Pubitemid 34175086)
16. Press N, Tyndall MW, Wood E, Hogg RS, Montaner JS. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S112-7. (Pubitemid 35453569)
17. Raffa JD, Tossonian HK, Grebely J, Petkau AJ, DeVlaming S, Conway B. Intermediate highly active antiretroviral therapy adherence thresholds and empirical models for the development of drug resistance mutations. J Acquir Immune Defic Syndr. 2008;47(3):397-9. (Pubitemid 351619429)
18. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav. 2006;10(3):227-45.
19. Munoz-Moreno JA, Fumaz CR, Ferrer MJ, Tuldra A, Rovira T, Viladrich C, et al. Assessing self-reported adherence to HIV therapy by questionnaire: The SERAD (Self-Reported Adherence) Study. AIDS Res Hum Retroviruses. 2007;23(10): 1166-75. (Pubitemid 350017601)
20. Knobel H, Codina C, Miro JM, Carmona A, Garcia B, Antela A, et al. The recommendations of GESIDA/SEFH/PNS for improving adherence to antiretroviral treatment. AIDS Study Group of the Spanish Society of Hospital Pharmacy and the National Plan on AIDS of the Minister of Health and Consumers. Enferm Infecc Microbiol Clin. 2000;18(1):27-39. (Pubitemid 30143075)
21. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79-87. (Pubitemid 44885645)
22. Nieuwkerk P, Oort F. Self-report adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: A meta-analysis. JAIDS. 2005;38(4):445-8. (Pubitemid 40381555)
23. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of selfreport and electronic monitoring. Clin Infect Dis. 2001;33(8): 1417-23. (Pubitemid 32955198)
24. Pearson CR, Simoni JM, Hoff P, Kurth AE, Martin DP. Assessing antiretroviral adherence via electronic drug monitoring and self-report: An examination of key methodological issues. AIDS Behav. 2007;11(2):161-73.
25. Nieuwkerk PT, der Kolk IM, Prins JM, Locadia M, Sprangers MA. Self-reported adherence is more predictive of virological treatment response among patients with a lower tendency towards socially desirable responding. Antivir Ther. 2010;15(6): 913-6.
26. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003;17(4):169-77. (Pubitemid 36444006)
27. Puigventós F, Riera M, Delibes C, Peñaranda M, de la Fuente L, Boronat A. Estudios de adhrencia a los fármacos antirretrovirales. Medicina Clínica. 2002;119(4):130-7. (Pubitemid 35256342)
28. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: A meta-analysis. JAMA. 2006;296(6): 679-90. (Pubitemid 44200639)
29. Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/ acquired immune deficiency syndrome among drug users: A systematic review. Addiction. 2008;103(8):1242-57. (Pubitemid 352009054)
30. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-12. (Pubitemid 30214957)
31. AETC. AIDS Education and Training Centers. National Resource Center. HIV Classification: CDC and WHO Staging Systems. 2011; Available at: Http://www.aids-ed.org/aidsetc?page=cm-105-disease#t-1. Accessed 23 January 2011.
32. Vandenbroucke JP, Von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration. Gac Sanit. 2009;23(2):158.
33. United Nations Development Programme. Statistics of the human development report. New York: Oxford University Press; 2008.
34. World Bank. World Development Indicators 2007. CD-ROM. Washington, DC; 2007
35. Hedges LV, Pigott TD. The power of statistical tests for moderators in meta-analysis. Psychol Methods 2004;9:426-45. (Pubitemid 40005041)
36. Lipsey MW, Wilson D. Practical meta-analysis. London: Sage; 2001.
37. Duval S, Tweedie R. Trim and Fill: A simple funnel-plot-based method of testing and adjusting for publication bias in metaanalysis. Biometrics. 2000;(56):455-63. (Pubitemid 30422636)
38. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;4(50): 1088-101.
39. Egger M, Davey G, Schneider M, Minder C. Bias in metaanalysis detected by a simple graphical test. BMJ 1997;315: 629-34. (Pubitemid 27387172)
40. Huedo T, Sánchez-Meca J, Marín F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193-206. (Pubitemid 44001277)
41. Hedges LV, Vevea JL. Estimating effect size under publication bias: Small sample properties and robustness of a random effects selection model. J Educ Behav Stat. 1996;21:299-333.
42. Aiken LS, West SG. Multiple regression: Testing and interpreting interactions. Newbury Park, CA: Sage; 1991.
43. Hedges L, Pigott TD. The power of statistical tests in metaanalysis. Psychol Methods. 2001;3(6):203-17.
44. Kitahata MM, Reed SD, Dillingham PW, Van Rompaey SE, Young AA, Harrington RD, et al. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS. 2004;15(12):803-10. (Pubitemid 40018704)
45. Lima VD, Bangsberg DR, Harrigan PR, Deeks SG, Yip B, Hogg RS, et al. Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr. 2010;55(4): 460-5.
46. Moatti JP, Spire B, Kazatchkine M. Drug resistance and adherence to HIV/AIDS antiretroviral treatment: Against a double standard between the north and the south. AIDS. 2004;18(Suppl 3):S55-61. (Pubitemid 39037461)
47. Nachega JB, Stein DM, Lehman DA, Hlatshwayo D, Mothopeng R, Chaisson RE, et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses. 2004;20(10):1053-6. (Pubitemid 39392009)
48. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS. 2003;17(9):1369-75. (Pubitemid 36819851)
49. Abaasa AM, Todd J, Ekoru K, Kalyango JN, Levin J, Odeke E, et al. Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: The experience of The AIDS Support Organization (TASO), Kampala, Uganda. BMC Health Serv Res. 2008;8:241.
50. Abellan J, Garrote M, Pulido F, Rubio R, Costa JR. Evaluation of adherence to a triple antiretroviral therapy in HIV-positive patients. Eur J Intern Med. 1999;10:202-5. (Pubitemid 30042912)
51. Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28(5):445-9. (Pubitemid 34033195)
52. Applebaum AJ, Reilly LC, Gonzalez JS, Richardson MA, Leveroni CL, Safren SA. The impact of neuropsychological functioning on adherence to HAART in HIV-infected substance abuse patients. AIDS Patient Care STDS. 2009;23(6):455-62.
53. Applebaum AJ, Richardson MA, Brady SM, Brief DJ, Keane TM. Gender and other psychosocial factors as predictors of adherence to Highly Active Antiretroviral Therapy (HAART) in adults with comorbid HIV/AIDS, psychiatric and substancerelated disorder. AIDS Behav. 2009;13(1):60-5.
54. Assis F, Puig-Junoy J, Fátima P, Gracas M, Drew M. Análisis coste-efectividad de la adhesión inicial a la terapia antirretroviral entre individuos infectados por el VIH en Belo horizonte (Brasil). Revista Española Salud Pública. 2006;80(1):41-54. (Pubitemid 44383631)
55. Barfod TS, Gerstoft J, Rodkjaer L, Pedersen C, Nielsen H, Moller A, et al. Patients' answers to simple questions about treatment satisfaction and adherence and depression are associated with failure of HAART: A cross-sectional survey. AIDS Patient Care STDS. 2005;19(5):317-25. (Pubitemid 40770655)
56. Beyene KA, Gedif T, Gebre-Mariam T, Engidawork E. Highly active antiretroviral therapy adherence and its determinants in selected hospital from south and central Ethiopia. Pharmacoepidemiol Drug Saf. 2009;18(11):1007-15.
57. der Kolk IM, Sprangers MA, van der Ende M, Schreij G, de Wolf F, Nieuwkerk PT. Lower perceived necessity of HAART predicts lower treatment adherence and worse virological response in the ATHENA cohort. J Acquir Immune Defic Syndr. 2008;49(4):460-2.
58. Brañas F, Berenguer J, Sanchez-Conde M, Lopez-Bernaldo de Quiros JC, Miralles P, Cosin J, et al. The eldest of older adults living with HIV: Response and adherence to highly active antiretroviral therapy. Am J Med. 2008;121(9):820-4.
59. Brown S, Friedland GH, Bodasing U. Assessment of adherence to antiretroviral therapy in HIV-infected Southe African adults. XV International AIDS Conference 2004 July 11-16, 2004 Bangkok, Thailand (Abstract B12223).
60. Buathong N, Hiransuthikul N, Tangwongchai S, Komoltri C. Association between depression and adherence to highly active antiretroviral therapy among adult HIV infected patients in Thailand. Asian Biomed. 2009;3(2):127-33.
61. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIV? Ugandan patients purchasing therapy. Int J STD AIDS. 2005;16(1):38-41. (Pubitemid 40193660)
62. Carballo E, Cadarso-Suarez C, Carrera I, Fraga J, de la Fuente J, Ocampo A, et al. Assessing relationships between health-related quality of life and adherence to antiretroviral therapy. Qual Life Res. 2004;13(3):587-99. (Pubitemid 38526534)
63. de Carvalho CV, Duarte DB, Merchan-Hamann E, Bicudo E, Laguardia J. Predictors of compliance with highly active antiretroviral therapy in Brasilia, Distrito Federal, Brazil, 1999-2000. Cad Saude Publica. 2003;19(2):593-604.
64. Codina J, Tuset M, Ibarra O, Delgado O, Morancho O, García B. Evaluación de un programa de atención farmacéutica dirigido a mejorar la adherencia al tratamiento antirretroviral. Farmacia Hospitalaria 2004;Supl. 1(28):25-32.
65. Cruess DG, Minor S, Antoni MH, Millon T. Utility of the Millon Behavioral Medicine Diagnostic (MBMD) to predict adherence to highly active antiretroviral therapy (HAART) medication regimens among HIV-positive men and women. J Pers Assess. 2007;89(3):277-90. (Pubitemid 350274951)
66. Daniel OJ, Ogun SA, Odusoga OL, et al. Adherence pattern to ARV drugs among AIDS patients on self-purchased drugs and those on free medications in sagamu, Nigeria. XV International AIDS Conference 2004 July 11-16; 2004 Bangkok (Thailand) (WePeB5768).
67. Diabaté S, Alary M, Koffi CK. Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Cote d'Ivoire. AIDS. 2007;21(13):1799-803. (Pubitemid 47237568)
68. Eholié SP, Tanon A, Polneau S, Ouiminga M, Djadji A, Kangah-Koffi C, et al. Field adherence to highly active antiretroviral therapy in HIV-infected adults in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr. 2007;45(3):355-8. (Pubitemid 47012385)
69. Escobar I, Campo M, Martin J, Fernandez-Shaw C, Pulido F, Rubio R. Factors affecting patient adherence to highly active antiretroviral therapy. Ann Pharmacother. 2003;37(6):775-81. (Pubitemid 36618359)
70. Fong OW, Ho CF, Fung LY, Lee FK, Tse WH, Yuen CY, et al. Determinants of adherence to highly active antiretroviral therapy (HAART) in Chinese HIV/AIDS patients. HIV Med. 2003;4(2):133-8. (Pubitemid 36582296)
71. Fumaz CR, Munoz-Moreno JA, Molto J, Ferrer MJ, Lopez-Blazquez R, Negredo E, et al. Sustained antiretroviral treatment adherence in survivors of the pre-HAART era: Attitudes and beliefs. AIDS Care. 2008;20(7):796-805.
72. Garciá de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30(1):105-10. (Pubitemid 34506694)
73. Gibbie T, Hay M, Hutchison CW, Mijch A. Depression, social support and adherence to highly active antiretroviral therapy in people living with HIV/AIDS. Sex Health. 2007;4(4):227-32. (Pubitemid 350158745)
74. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13(13):1763-9. (Pubitemid 30015725)
75. Guaraldi G, Murri R, Orlando G, Orlandi E, Sterrantino G, Borderi M, et al. Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. HIV Clin Trials. 2003;4(2):99-106. (Pubitemid 36410913)
76. Harvey KM, Carrington D, Duncan J, Figueroa JP, Hirschorn L, Manning D, et al. Evaluation of adherence to highly active antiretroviral therapy in adults in Jamaica. West Indian Med J. 2008;57(3):293-7.
77. Herraiz F, Villamarín F, Chamarro A. Correlatos psicosociales de la adhesión al tratamiento antirretroviral en el Centro Penitenciariode hombres de Barcelona. Rev esp sanid penit. 2008;10(3):80-9.
78. Hicks PL, Mulvey KP, Chander G, Fleishman JA, Josephs JS, Korthuis PT, et al. The impact of illicit drug use and substance abuse treatment on adherence to HAART. AIDS Care. 2007;19(9):1134-40. (Pubitemid 350223192)
79. Horne R, Cooper V, Gellaitry G, Date HL, Fisher M. Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: The utility of the necessity-concerns framework. J Acquir Immune Defic Syndr. 2007;45(3):334-41. (Pubitemid 47012382)
80. Hosseinipour MC, Neuhann F, Kanyama C, et al. Safety and efficacy of D4T/3Tc/NVP hmong HIV positive adults in Lilongwe, Malawi. eJournal of International AIDS Conference 2004 July 11-16.
81. Idigbe EO, Adewole TA, Eisen G, Kanki P, Odunukwe NN, Onwujekwe DI, et al. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: A preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr. 2005;40(1):65-9. (Pubitemid 41233207)
82. Iliyasu Z, Kabir M, Abubakar IS, et al. Compliance to antiretroviral therapy among AIDS patients in Aminu Kano Teaching Hospital, Kano, Nigeria. Niger J Med. 2005;14:290-4.
83. Ines SM, Moralejo L, Marcos M, Fuertes A, Luna G. Adherence to highly active antiretroviral therapy in HIV-infected inmates. Curr HIV Res. 2008;6(2):164-70. (Pubitemid 351479795)
84. Kalanzi D, Nansikombi J. Texas Woman's U., US. Adherence behavior and the impact of HAART on quality of life of Ugandan adults; 2008.
85. Kerr T, Palepu A, Barness G, Walsh J, Hogg R, Montaner J, et al. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver. Antivir Ther. 2004;9(3):407-14. (Pubitemid 38878756)
86. Kleeberger CA, Buechner J, Palella F, Detels R, Riddler S, Godfrey R, et al. Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study. AIDS. 2004;18(4):683-8. (Pubitemid 38393468)
87. Knobel H, Alonso J, Casado JL, Collazos J, González J, Ruiz I, et al. Validation of a simplified medication adherence questionaire in a large cohorte of HIV-infected patients: The GEEMA study. AIDS 2002;16:605-13. (Pubitemid 34218856)
88. Knobel H, Guelar A. Estrategias para optimizar la adherencia al tratamiento antirretroviral. Intervenciones en la pauta terapéutica. Enfermedades Infecciosas y Microbiología Clínica. 2004; 2(22):106-12. (Pubitemid 38585450)
89. Kumar V, Encinosa W. Effects of antidepressant treatment on antiretroviral regimen adherence among depressed HIV-infected patients. Psychiatr Q. 2009;80(3):131-41.
90. Ladero Martín L, Orejudo Hernández S, Carrobles Isabel J, Malo Aznar C. Consumo de drogas y adherencia a la terapia antirretroviral de pacientes en programa de mantenimiento con metadona. Adicciones. 2005;17(3):203-14. (Pubitemid 41564425)
91. Lattuada E, Lanzafame M, Gottardi M, Corsini F, Concia E, Vento S. Initial hospitalization and adherence to highly active antiretroviral therapy. Clin Infect Dis. 2008;46(6):957-8. (Pubitemid 351417211)
92. Lee SS, Ma K, Chu EKY, Wong KH. The phenomenon of missing doses in a cohort of HIV patients with good adherence to highly active antiretroviral therapy. Int J STD AIDS. 2007; 18(3):167-70. (Pubitemid 351739045)
93. Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS. 2008;22(17):2371-80.
94. Marco A, Gallego C, Lonca M, Pérez-Amigó P, Monfort A, Gramunt J, et al. Estudio multicéntrico penitenciario sobre adherencia a corto plazo de una pauta antirretroviral con Nelfinavir y/o Saquinavir. Rev esp sanid penit. 2002;4(1):4-9.
95. Martín MT, del Cacho E, López E, Codina C, Tuset M, de Lazzari E, et al. Reacciones adversas del tratamiento antirretroviral relación entre los síntomas percibidos y el cumplimiento terapéutico. Medicina Clínica. 2007;4(129):127-33. (Pubitemid 47400823)
96. Martin J, Escobar I, Rubio R, Sabugal G, Cascon J, Pulido F. Study of the validity of a questionnaire to assess the adherence to therapy in patients infected by HIV. HIV Clin Trials. 2001;2(1):31-7. (Pubitemid 32181747)
97. Martín V,Ortega L, Pérez MR, Mostaza JL, Ortiz de Urbina JJ, Rodriguez M, et al. Factores predictores de no adherencia al tratamiento antirretroviral de gran actividad. Enferm infecc microbiol clín (Ed impr) 2002;20(10):491-7.
98. Merenstein D, Schneider MF, Cox C, Schwartz R, Weber K, Robison E, et al. Association of child care burden and household composition with adherence to highly active antiretroviral therapy in the Women's Interagency HIV Study. AIDS Patient Care STDS. 2009;23(4):289-96.
99. Mohammed H, Kieltyka L, Richardson-Alston G, Magnus M, Fawal H, Vermund SH, et al. Adherence to HAART among HIV-infected persons in rural Louisiana. AIDS Patient Care STDS. 2004;18(5):289-96. (Pubitemid 38720319)
100. Moralejo L, Ines S, Marcos M, Fuertes A, Luna G. Factors influencing adherence to highly active antiretroviral therapy in Spain. Curr HIV Res. 2006;4(2):221-7.
101. Morillo R, Abdel L, Márquez E, Martínez I, Artacho S, Almeida C, et al. Análisis de las causas de suspensión del régimen antirretroviral simplificado abacavir, lamivudina y zidovudina. Farmacia Hospitalaria. 2005;29(3):164-70.
102. Nieuwkerk PT, Sprangers MA, Burger DM, Hoetelmans RM, Hugen PW, Danner SA, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 2001;161(16): 1962-8.
103. Owen-Smith A, Diclemente R, Wingood G. Complementary and alternative medicine use decreases adherence to HAART in HIV-positive women. AIDS Care. 2007;19(5):589-93. (Pubitemid 46763748)
104. Parruti G, Manzoli L, Toro PM, D'Amico G, Rotolo S, Graziani V, et al. Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: Predictors and impact on virologic response and relapse. AIDS Patient Care STDS. 2006;20(1):48-56.
105. Penedo FJ, Gonzalez JS, Dahn JR, Antoni M, Malow R, Costa P, et al. Personality, quality of life and HAART adherence among men and women living with HIV/AIDS. J Psychosom Res. 2003;54(3):271-8. (Pubitemid 36388865)
106. Peretti-Watel P, Spire B, Pierret J, Lert F, Obadia Y. VESPA Group. Management of HIV-related stigma and adherence to HAART: Evidence from a large representative sample of outpatients attending French hospitals (ANRS-EN12-VESPA 2003). AIDS Care. 2006;18(3):254-61.
107. Pradier C, Carrieri P, Bentz L, Spire B, Dellamonica P, Moreau J, et al. Impact of short-term adherence on virological and immunological success of HAART: A case study among French HIV-infected IDUs. Int J STD AIDS. 2001;12(5):324-8. (Pubitemid 32453139)
108. Protopopescu C, Raffi F, Roux P, Reynes J, Dellamonica P, Spire B, et al. Factors associated with non-adherence to longterm highly active antiretroviral therapy: A 10 year follow-up analysis with correction for the bias induced by missing data. J Antimicrob Chemother. 2009;63(3):599-606.
109. Quiros-Roldan E, Torti C, Lapadula G, Ladisa N, Micheli V, Patroni A, et al. Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy. AIDS Patient Care STDS. 2007;21(2):92-9. (Pubitemid 46394022)
110. Ramadhani HO, Thielman N, Landman K, et al. Predictors of maladherence hmong patients receiving fixed dose combination Statvudine/Lamivudine/Nevirapine in Northern Tanzania. 2006 February 5-8, Denver, Colo.
111. Remor E. Infección por VIH y Sida: Características psicológicas y adhesión al tratamiento. 2000 Dpto. Psicología Biológica y de la Salud. Universidad Autonoma Madrid.
112. Riera M, la Fuente L, Castanyer B, Puigventós F, Villalonga C, Ribas MA, et al. Adherencia a los fármacos antirretrovirales medida por la concentración de fármacos y el recuento de comprimidos. Variables relacionadas con una mala adherencia. Medicina Clínica. 2002;119(8):286-92. (Pubitemid 35189959)
113. Roca B, Lloria N. Adherence and viral load response to HAART. AIDS. 2000;14:P109.
114. Roca B, Lapuebia C, Edo MT, Ballester R. Causes of nonadherence to HAART. AIDS. 2000;14:P127.
115. Rodríguez Torné G, Iranzu Aperte M, Berrocal Javato M, Gómez-Serranillo Reus M. Adherencia al tratamiento antirretroviral: Repercusión del número de tomas diarias. Revista de la O F I L. 2007;17(3):15-20.
116. Royal SW, Kidder DP, Patrabansh S, Wolitski RJ, Holtgrave DR, Aidala A, et al. Factors associated with adherence to highly active antiretroviral therapy in homeless or unstably housed adults living with HIV. AIDS Care. 2009;21(4):448-55.
117. Ruiz I, Orly A, Prada JL, Rodríguez J, Causse M, López MA, et al. Impacto de los factores demográficos y psicosociales en la no adherencia a los fármacos antirretrovirales. Enfermedades infecciosas y microbiologia clinica. 2006;24(6):373-8.
118. Shaahu VN, Lawoyin TO, Sangowawa AO. Adherence to highly active antiretroviral therapy (HAAT) at a Federal Medical Centre. Afr J Med Med Sci. 2008;37(1):29-36.
119. Sledjeski EM, Delahanty DL, Bogart LM. Incidence and impact of posttraumatic stress disorder and comorbid depression on adherence to HAART and CD4+ counts in people living with HIV. AIDS Patient Care STDS. 2005;19(11):728-36. (Pubitemid 41705169)
120. Tornero C, Cuenca A, Nolasco A, Soler E, Rull S. Gasto farmacéutico en medicación antirretroviral y posibilidades de optimización. Anales de Medicina Interna. 2005;22(12):575-8. (Pubitemid 44973419)
121. Trotta MP, Ammassari A, Cozzi-Lepri A, Zaccarelli M, Castelli F, Narciso P, et al. Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. AIDS. 2003;17(7):1099-102. (Pubitemid 36549729)
122. Tuldrà A, Ferrer MJ, Fumaz C, Bayés R, Paredes R, Burger DM, et al. Monitoring adherence to HIV therapy. Arch Intern Med. 1999;159:1376-7.
123. van Oosterhout JJ, Bodasing N, Kumwenda JJ, Nyirenda C, Mallewa J, Cleary PR, et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health. 2005;10(5):464-70. (Pubitemid 40712431)
124. Ventura Cerdá J, Minguez Gallego C, Fernández Villalba E, Alós Almiñana M, Andrés Soler J. Escala simplificada para detectar problemas de adherencia (ESPA) al tratamiento antirretroviral. Farmacia Hospitalaria. 2006;30(3):171-6.
125. Viciana P, Rubio R, Ribera E, Knobel H, Iribarren JA, Arribas JR, et al. Estudio longitudinal de adherencia, satisfacción y efectividad del tratamiento antirretroviral administrado una vez al día, frente a dos veces al día, en una cohorte española de infectados por el VIH (estudio CUVA: Cualquiera una vez al día). Enferm infecc microbiol clín (Ed impr). 2008;26(3): 127-34. (Pubitemid 351416484)
126. Vriesendorp R, Cohen A, Kristanto P, Vrijens B, Rakesh P, Anand B, et al. Adherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in Botswana. Eur J Clin Pharmacol. 2007;63(12):1115-21. (Pubitemid 350112758)
127. Weiss L, French T, Finkelstein R, Waters M, Mukherjee R, Agins B. HIV-related knowledge and adherence to HAART. AIDS Care. 2003;15(5):673-9. (Pubitemid 37193856)
128. Williams M, Clarke T, Williams P, Barton EN. The mean levels of adherence and factors contributing to non-adherence in patients on highly active antiretroviral therapy. West Indian Med J. 2007;56(3):270-4. (Pubitemid 350200074)
129. Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 2003;169(7):656-61. (Pubitemid 37266973)
130. Zorrilla CD, Santiago LE, Knubson D, Liberatore K, Estronza G, Colon O, et al. Greater adherence to highly active antiretroviral therapy (HAART) between pregnant versus non-pregnant women living with HIV. Cell Mol Biol (Noisy-le-grand). 2003;49(8):1187-92.